Evommune, Inc. (EVMN) stock
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$6.88−0.14 (-1.99%)
Close on Nov 18, 2026Market cap $249.69MP/E –Yield –
Evommune net income
Net income is the profit left for shareholders after every expense, interest and tax.
Evommune's net income for the twelve months ending Sep 30, 2026 was -$113.07M. For fiscal 2025 it was -$68.87M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$68.87M | – |
| FY2024 | Dec 31, 2024 | -$66.81M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$30.88M | – |
| Q2 FY2026 | Jun 30, 2026 | -$32.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.67M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.92M | – |
See a number that looks wrong?